職位描述
崗位職責：
1.根據公司政策及程序指引下從事醫學信息溝通，達成公司指標；
2.及時提供市場信息并做出適當建議；
3.推廣所負責的產品，給客戶提供產品的相關學術信息；
4.開發及常規拜訪客戶并與其建立良好關系，保持公司形象；
任職條件：
1. 本科或以上學歷，醫學，藥學，生命科學等相關專業；
2. 具有良好的銷售溝通技巧，善于自我激勵和承受壓力；
3. 熟練使用辦公軟件，英語良好；
4.有一定的腫瘤類醫藥銷售經驗尤佳。
企業簡介
企業介紹
ENTERPRISE PROFILE
泰凌總部位于香港，在上海、北京、廣州設有投資、營銷管理、研發及醫學事務中心，在蘇州、泰州、長沙及瑞士建有生產基地。目前，集團擁有20余家子公司。
NT PHARMA'S HEADQUARTER IS BASED IN HONG KONG WHICH INCLUDES INTERNATIONAL BUSINESS AND INVESTMENT GROUP. MARKETING MANAGEMENT, RESEARCH AND DEVELOPMENT AND MEDICAL BUSINESS CENTRES ARE BASED IN SHANGHAI, BEIJING,AND GUANGZHOU. OUR PRODUCTION AND MANUFACTURING FACTORIES ARE BASED IN SUZHOU, TAIZHOU, CHANGSHA AND SWITZERLAND. CURRENTLY NT PHARMA GROUP HAS MORE THAN 20 SUBSIDIARIES.
集團的核心產品覆蓋了腫瘤及血液系統疾病、骨代謝疾病、消化系統疾病、中樞神經系統疾病、呼吸系統疾病等多個治療領域，主要有：國際著名骨科品牌“密蓋息”(鮭魚降鈣素)，國家1.1類腫瘤新藥“喜滴克”（尿多酸肽注射液），國家肝病新藥“松梔丸”，品牌仿制藥“舒思”（富馬酸喹硫平片）等20余種產品。這些藥品覆蓋了中國除西藏、臺灣以外的廣大地區，近20,000家醫療機構，并受到中國醫療機構的廣泛認同。
WE FOCUS ON DEVELOPMENT OF CORE PRODUCTS OF OUR BRAND COVERING TUMOUR AND BLOOD SYSTEM DISEASES, DIGESTIVE SYSTEM DISEASES, CENTRAL NERVOUS DISEASES, DISEASES OF RESPIRATORY SYSTEM AND OTHER THERAPEUTIC FIELDS. OUR MAIN PRODUCTS INCLUDES: WORLD RENOWNED ORTHOPAEDIC BRAND "MIACALCIC" (SALMON CALCITONIN), NATIONAL 1.1-CLASS NEW TUMOR DRUG "XIDIKE" (UROACITIDES INJECTION), NATIONAL HEPATIC NEW DRUG "SONGZHI PILL", BRAND GENERIC DRUG "SHUSI" (FUMARIC ACID QUETIAPIEN TABLETS) AND 20+ OTHER PRODUCTS. OUR PRODUCTS HAVE BEEN DISTRIBUTED BY MORE THAN 20,000 MEDICAL INSTITUTIONS ALL OVER CHINA EXCEPT FOR TIBET AND TAIWAN AND IS WIDELY RECOGNIZED BY CHINESE MEDICAL INSTITUTIONS.
泰凌自創建以來，一直致力于成為面向世界的國際化醫藥企業，“密蓋息”遠銷世界20余個國家地區，“舒思”遠銷歐洲市場。同時，與諸多世界領先跨國醫藥企業建立了長期戰略合作關系，包括葛蘭素史克(GSK)、輝瑞(Pfizer)、羅氏(Roche)、諾華(Novartis)、貝朗(B|BRAUN)等。
SINCE OUR ESTABLISHMENT, NT PHARMA HAS BEEN DEVOTED TO BECOME A WORLD-ORIENTED INTERNATIONALIZED PHARMACEUTICAL ENTERPRISE. "MIACALCIC" HAS BEEN USED IN MORE THAN 20 COUNTRIES AND REGIONS. "SHUSI" HAS ITS STRONG MARKETS IN EUROPE MARKET MEANWHILE NT PHARMA HAS MANY LONG-TERM STRATEGIC COOPERATION RELATION WITH WORLD LEADING MULTINATIONAL PHARMACEUTICAL ENTERPRISES INCLUDING GLAXOSMITHKLINE (GSK), PFIZER, ROCHE, NOVARTIS AND BIBRAUN.
[展開全文]
[收縮全文]
